Compare Amylx Pharmaceuticals Inc (AMLX) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs DoorDash Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while DoorDash Inc trades at $192 (market cap $83.58B). The key difference: DoorDash Inc is far larger — about 42.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | DASH | |
|---|---|---|
Market Cap | $1.98B | $83.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $281.74 |
52-Week Low | $7.64 | $146.60 |
Enterprise Value | $1.70B | $81.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
DoorDash (DASH) trades at $191.82, down 0.28% on the day, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $13.72 billion in 2025, and has turned profitable with a net income margin of 6.29%. Recent news highlights expansion into grocery delivery and AI integration, while technical indicators suggest key resistance near $200.
The outlook remains positive due to market dominance and international expansion, but risks include intense competition and valuation concerns with a P/E of 90.91. Analysts project a consensus price target of $231.50, implying significant upside, though upcoming Q2 2026 earnings on August 5 will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
